Sildenafil citrate

CHF 135.00
In stock
CDX-S0078-M05050 mgCHF 135.00
CDX-S0078-M250250 mgCHF 543.00
More Information
Product Details
Synonyms 5-[2-Ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one citrate salt; Actra-Rx; Edegra; Viagra; Tonafil; Apodefil; UK 92480
Product Type Chemical
Formula C22H30N6O4S . C6H8O7
MW 474.6 . 192.1
CAS 171599-83-0
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO (20mg/ml).
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Smiles OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Potent cGMP-specific phosphodiesterase inhibitor that is highly selective for PDE5. It inhibits PDE5 activity in isolated rabbit platelets with an IC50 value of 3.6nM (3nM in human corpus cavernosum) compared to inhibition of PDE1 and PDE3 activities (IC50s = 0.26 and 65μM, respectively). Inhibition of PDE5 enhances the relaxation of smooth muscle in a range of vascular tissues by prolonging the nitric oxide/cGMP-mediated activation of cGMP-dependent protein kinase. While most notable for its use in the treatment of erectile dysfunction, sildenafil’s vasorelaxant properties have also been used to control vascular tone in pulmonary arterial hypertension and high-altitude pulmonary edema associated with altitude sickness. The citrate salt has superior water solubility and pharmacokinetics compared to the base salt of sildenafil.

Product References

(1) N.K. Terrett, et al.; Bioorg. Med. Chem. Lett. 6, 1819 (1996) | (2) J. Richalet, et al.; Am. J. Respir. Crit. Care Med. 171, 275 (2005) | (3) C.E. Teixeira, et al.; J. Pharmacol. Exp. Ther. 316, 654 (2006) | (4) S. Jung, et al.; Arch. Pharm. Res. 34, 451 (2011)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.